Member Info for Birdseye

With money to support the next couple of months and the possibility of taking another $2m off Hercules if needed why would they bother before the possibility of FDA approval ?

If approved then a 7p placing would be cheap let alone 3p.

This month will drag here.

Sandy please feel free to sell up and leave, don't worry I will turn everything off and lock up for you when you have gone.

Why are your comments always so derampy ? Probably why I dislike you so much, that and the name, DrSandy97. Is 97 the year you was born, sounds as realistic as your half glass empty comments.

Then just put a warning for 2% on the label. Why would you seek to take so much more time and money.

Don't think there will be any trials like everybody has been saying, no mention of such.

Amazing how they dropped it back with FA.

Clearly wasn't asking you to give me the answer Sandy.

Iclaprim has received Qualified Infectious Disease Product (QIDP) designation from the FDA together with Fast Track status for the ABSSSI indication. If approved for the ABSSSI indication as a New Chemical Entity, iclaprim will be eligible for 10 years of market exclusivity in the U.S. from the date of first approval, under the Generating Antibiotic Incentives Now Act (the GAIN Act). In Europe, 10 years of market exclusivity is anticipated. Motif is also building a patent estate to provide additional protection for iclaprim and has two U.S. method of use patents issued that will expire in 2037.

Knew I read something along them lines.

You mentioned the European submission taking a year to do and why haven’t they done it. Doesn’t America have a 5 year exclusivity? I may have read this on another stock tbh so not 100% sure.

Can anyone confirm.

Wow Thoth, considering your deep in SAR I would say it’s you who has the wisdom of picking diluted turds. Your sp is 3/4 of 1p.
Thanks for stopping by.

Nice to read the naysayers are now on board and now talking ramping bull Ox.
RNS is the only confirmation we need and not speculative drivel.
Meeting isn't even confirmed date let alone instant approval .

For a month at least now, small director buy to cover a delay.

DR Sandy, wind your neck in.
You have had an lse account 5 mins and apparently your a concerned long time holder that spouts horse shi7 calling out questions only the bod can really answer in a way that just makes you look a blatant deramper trying to lower the price.
I'm no LTH but I am a holder and will see it through but you clearly have a view to a kill.
I would expect a doctor to be more respectful but really its just clarification your a charlatan and anyone replying to your fake account may as well call you DR Dickwad.

7p

To be fair, your both speaking the truth.
The wording could mean months or this week for all we know.

No point going on about it tbh as its down to the Bod .

That's my feeling too waccy .
Would get better terms once they have sat the meeting with FDA hopefully.

Will turn up one day soon with his iclaprim gun and start shooting the Autobots.

Thank you FM

I want to know right now is the date of the FDA meeting and then the outcome.
Is the meeting expected to be held in 4 weeks or is that the amount of time needed just to get a meeting date off them ?

The unexpected CRL for iclaprim is clearly a setback for Motif, however we are hopeful the company will be able to better understand the FDA’s concerns and get clarity regarding what additional information will be necessary in order to refile the NDA. We anticipate an update in the next couple of months following the Type A meeting with the FDA. Reducing the debt load was a smart move, particularly as the company looks to raise additional capital in the near future. With the uncertainty surrounding the approval of iclaprim and the necessity to raise additional capital following the significant decrease in the share price we have made significant changes to our model that has resulted in lowering our valuation to $7 per share, although this valuation is highly fluid and ultimately will be dictated by the outcome of the FDA meeting.

From an interview.

Funding after meeting ?

Lol, as if magic.
Only the rocket injector to go

Some chunky buys all of a sudden would say your right.